Like a few other individuals on this board, I agree with

New Post Public Reply Private Reply Replies (2) Message Board
MGK_2
810
Like a few other individuals on this board, I agree with putting Pestell in the camp of 13D. He was their largest contributor. Without him, there was no 13D by sheer quantity of his holdings.

Really, when someone was at least the "backer" of such a parasitical group like 13D, how can he be found not to be just that.

Using CYDY for his prostate test, being Chief Medical Officer, sucking the life out of a trial by questioning LL's safety profile?, the 8.3 million shares and now another 7 million to boot? He has literally sucked the blood from his host organism. Does all this not prove his parasitical feeding on CytoDyn, using his CCR5 knowledge as his free pass to feed on what his heart desires?

I align him with Amarex. I only have a suspicion, but the backers of the work which was committed against our HIV trial, to mutilate the BLA for HIV, had to be in collusion with Amarex to accomplish this deed, and it was achieved when 13D had not yet quite made their revelation. Had the BLA been received and Filed by the FDA, LL would be approved today for HIV and Covid 19 as well. The needless death of hundreds of thousands could have been prevented had Amarex done its job. Had, BP, and 13D not interfered with our trials.

There never would have been a 13D uprising or Amarex Arbitration for that matter. Nader would still be in charge. Covid would have been minimized.

Now, we have no Nader, we have the re-emergence of a parasite, the reminders of a 13D renaissance and how Amarex caused all of this to go down.

A curve ball thrown to the shareholders. CytoDyn negotiates with 13D? What would be the benefit? Obviously... there must be some great benefit. Right? given the magnitude of the award. Why did we not shut him down completely, but opted to settle the case even a week early, in the way that we did?

Was it Karen Brunke who liked his CCR5 understanding? Does she feel he would help her figure out new LL indications? Were they looking to free up a board position and knew Jordan Naydenov would leave with that settlement? There must have been reasons which made it worth far more than that.

Who does he know? What corporations is he affiliated with? In what capacity? What was discussed prior to the decision to make this grand settlement? What was implied in the statement, "Dr. Pestell and the Company are also exploring ways in which Dr. Pestell can reengage with the Company to help realize leronlimab’s full potential in oncology. CytoDyn regrets Dr. Pestell’s departure from the Company and the subsequent public statements made by its former CEO about Dr. Pestell."

What, He is not the parasite he once was? He only had it out for Nader and now, since Nader is gone, he will play nice?

Does he have any part of the collusion which had to have happened in Amarex? Is it too far fetched, to consider that he, with friends in high places, in the seats of the decision makers of Big Pharma, those that give the yea or nay on the treachery, the debauchery, in discussions, making recommendation, offering of advice. Yet, his name remains clean, devoid of any tarnish or flaw, polished with painstaking care to maintain it as flawless.

What is the value of the Amarex destruction? Minimum $13 Billion induced by the 13D. How would Sidley Austin have not advised against such a settlement if he were implicated in Amarex? Clearly, we expect more out of him than $13 Billion.

What if the opposite were true? What if he will now yield the truth to Sidley Austin on the BLA and Amarex? I wrote this in Taking a Look Ahead,

https://www.reddit.com/r/LeronLimab_Times/com...;context=3

"None are immune. All have deep pockets. All will be found out and discovered. The implications of which are enormous. CytoDyn swallows whole the elephant in the room. Negotiations? There will be nothing left to negotiate for, not even half an ear. No crumbs under the table. And Amarex will not be the only one consumed."

I also wrote, "CytoDyn needs to remain vigilant. Be careful of the covenants you sign CytoDyn. Leronlimab may not be breached. That must be forbidden. There can be no access to its assembly or manufacturing. There can be no understanding to its formula. There can be no decoding.

If for whatever reason, this is actually breached. all contracts / partnerships cease at once and CytoDyn goes it alone again. That must be written in every contract. Whoever would have breached this will be fighting with their best foot forward to again destroy CytoDyn."

Richard Pestell will not be CytoDyn's new CEO. He will however be CytoDyn's liaison in winning combination therapy partnerships with multiple Big Pharmaceuticals to broaden, strengthen and fortify the indications of their concluding monotherapy drugs for new use as combination therapy with Leronlimab. He will make amends and reap far greater rewards from his host in its rise than he ever has in its fall.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kyndryl's Sovereignty Strategy Tackles Digital Resilience

Updated Category News Views 22

Driving Resilience Amidst Sovereignty Moves Hot off the press, Kyndryl is rolling out a beefed-up strategy to fortify operational resilience in the face of shifting digital sovereignty challenges. I’d say these guys got their fingers firmly on the geopolitical pulse, and they’re not messing around. “Maintaining critical IT operations is fundamental to business...

Continue Reading
Four Seasons' New Palau Hub: A Game-Changer for Luxury

Updated Category News Views 74

Four Seasons Stirs Up the Luxury Travel Scene Alright, every once in a blue moon, you get this kind of roll-out from a hospitality giant that even gets a stone-cold trader to raise an eyebrow. Four Seasons isn't just any hotel chain; it's a heavyweight in the luxury sector. They're pulling the wraps off their new spot in Palau, and it's about as plush as it gets. They're...

Continue Reading
Clean Tech's Dual Role: Energy Resilience and Dependency

Updated Category News Views 83

Technology's Double-Edged Sword in Energy You ever chat with someone about moving your whole life onto solar? Seems greener and cheaper, right? But dive into the numbers, and you'll see it comes with its own set of strings attached. According to a fresh-off-the-press report from S&P Global, clean tech is both a saving grace and a looming liability economically and...

Continue Reading
Triller Faces Legal Storm: Investor Action Deadline Looms

Updated Category News Views 38

Triller Group Inc. Lands in Hot Water Ah, the stock market—it’s like playing poker in a storm. And here we stand, facing the mess Triller Group Inc. has gotten into. Known on the market as NASDAQ:ILLRW, Triller has caught itself in a legal tug-of-war over some nasty allegations. If you held shares during the period between October 16, 2024, and December 29, 2025, you...

Continue Reading
Keurig Dr Pepper's Bold $2B Offering: Strategic Shift

Updated Category News Views 23

Strategic Moves Behind KDP's $2 Billion Offering Walking through all this, Keurig Dr Pepper (NASDAQ:KDP) has set the stage for something big. Yeah, I'm talking about a hefty $2 billion underwritten public offering. It's one of those moves where you're either shaking your head in confusion or nodding in cautious approval. With the coffee behemoth taking this step, let's...

Continue Reading
Silicosis Crisis: Legal and Health Ramifications Loom

Updated Category News Views 58

The Hidden Dangers of Artificial Stone Here's the grim truth. Artificial stone countertops, loved by many for their aesthetics in kitchens and bathrooms, have a dark side that’s becoming increasingly hard to ignore. Loaded with more than 90% respirable crystalline silica, these materials spew out toxic dust when cut or polished. Once that dust gets airborne, workers...

Continue Reading
Tigo Energy Lawsuit: Shareholders' Fight for Justice

Updated Category News Views 63

Energy Optimism or Illusion? Is it a bright future when projections fizzle out faster than a lukewarm coffee on a cold morning? If you snapped up shares of Tigo Energy (NASDAQ: TYGO) thinking you were hitching your wagon to a rising solar star, the latest class action might just feel like a gut punch. Tangled Partnership Promises Let's cut to the core of the issue. Tigo...

Continue Reading
Flyers Fundraiser Supports Mental Health Advocacy in NJ and PA

Updated Category News Views 58

Blockbusters on Ice, Support Beyond the Rink Here's a twist for hockey fans out there: snagging tickets to catch the Philadelphia Flyers might pack more punch off the ice than on it. Why? Because, for every ticket you grab through Digital Elements Group's special link, $5 is pumped straight into the veins of mental health advocacy in New Jersey and Pennsylvania. Pretty...

Continue Reading
Universal Music CFO to Speak at Major Tech Conference

Updated Category News Views 42

UMG Steps into the Spotlight at Morgan Stanley Event Music, money, and technology—it's a compelling trio. Universal Music Group (EURONEXT: UMG) is sending its heavyweights, Matt Ellis and Michael Nash, to the Morgan Stanley European Technology, Media & Telecom Conference on November 18, 2026. This isn't just any run-of-the-mill industry hobnob. We're talking about the...

Continue Reading
Untapped $41B VA Loan Potential: Opportunities Missed

Updated Category News Views 137

VA Loans: Unused Potential Sits at $41 Billion Are you telling me we're leaving $41 billion just sitting on the table in the form of untapped VA loans? That's the figure staring us in the face according to Veterans United's latest analysis. It's not just about numbers; it's a head-scratcher given the growing VA loan market share, which hit 10% last year. Where's the...

Continue Reading

Top 5 Most Recently Viewed Articles

Kroll Liquidators Achieve Major Settlement with FTX Estate

Updated Category News Views 281

Kroll Liquidators Secure Significant Multi-Million Dollar Settlement In a notable development within the financial world, Kroll, the prominent independent provider of global financial and risk advisory solutions, has successfully facilitated a multi-million dollar settlement involving the liquidators of Emergent Fidelity Technologies and the FTX Estate. This important...

Continue Reading
EVgo Inc.’s Stellar Q3 2025 Performance Highlights Growth

Updated Category News Views 241

Outstanding Financial Results for Q3 2025 at EVgo Inc. EVgo Inc. (Nasdaq: EVGO), a key player in public fast charging for electric vehicles (EVs), has once again reported impressive financial outcomes for the third quarter of 2025. The total revenue for this period reached $92.3 million, marking a remarkable 37% increase year-over-year. This growth trend is indicative of...

Continue Reading
Inspired Entertainment Partners with Welcome Break for Innovation

Updated Category News Views 173

Inspired Entertainment's Strategic Partnership Extension Inspired Entertainment, Inc. (NASDAQ: INSE), a prominent name in the B2B gaming sector, recently announced an exciting continuation of its partnership with Welcome Break, recognized as a leading motorway service area operator in the UK. This collaboration, which now sees Inspired become the exclusive provider of...

Continue Reading
Discover 3 High-Yield Stocks with Impressive Returns

Updated Category News Views 140

Introduction to High-Yield Dividend Stocks When discussing dividend stocks, many investors often seek out those boasting high yields. In this article, we'll highlight three intriguing options that average around 12% yields. Interestingly, these stocks have garnered a considerable amount of skepticism from Wall Street analysts. The Current Market Sentiment Market analysts...

Continue Reading
NerdWallet Plans Q3 2024 Financial Results Call for Investors

Updated Category News Views 125

NerdWallet to Discuss Upcoming Financial Results NerdWallet, Inc. (NASDAQ: NRDS), a leading financial services platform dedicated to offering reliable financial guidance, is preparing to announce its third quarter financial results for 2024. This significant event is set for a specific date, along with a conference call designed to provide insights into these results....

Continue Reading